Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway

Figure 4

Effect of everolimus alone or both formononetin and everolimus on the mTOR pathway. MDA-MB-468 cells were treated with formononetin (150 µmol/L), everolimus (100 nmol/L), or both for 48 h. (a) PTEN, mTOR, Akt, P70S6K, and 4EBP-1 mRNA were identified using qRT-PCR analysis.p<0.05 versus control. (b) The expressions of mTOR, p-mTOR, Akt, p-Akt, PTEN, p-4EBP-1, and p-P70S6K were determined using Western blotting. (c) In the presence of Akt siRNA, the levels of p-mTOR, Akt, PTEN, p-4EBP-1, and p-P70S6K were observed on treatment with either everolimus alone or both formononetin and everolimus.

(a)

(b)

(c)